Read + Share
Drullinsky PR, Hurvitz SA. Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in
advanced breast cancer. Breast Cancer Res Treat 2020 Apr 9. pii: 10.1007/s10549-020-05618.
PMID: 32274666
|
 |
|
Drullinsky PR, Hurvitz SA. Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in
advanced breast cancer. Breast Cancer Res Treat 2020 Apr 9. pii: 10.1007/s10549-020-05618.
PMID: 32274666
|
|
|
|